Pramlintide
An FDA-approved synthetic analogue of amylin used alongside insulin for diabetes, also studied for weight management.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Pramlintide?
Pramlintide is a synthetic analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. It is FDA-approved as Symlin for use with mealtime insulin in type 1 and type 2 diabetes. Pramlintide slows gastric emptying, suppresses glucagon, and promotes satiety, complementing insulin therapy.
Why People Talk About It
Improved postprandial glucose control with insulin
StrongWeight loss in diabetic patients
ModerateAppetite suppression
ModerateHow It Works
Pramlintide replaces amylin, a hormone that diabetic patients lack. It slows down how fast food leaves your stomach, tells your liver to stop releasing extra sugar, and helps you feel full — all of which help control blood sugar after meals.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Must reduce insulin dose when starting pramlintide to avoid hypoglycemia
- • Not for patients with gastroparesis
- • Requires careful insulin dose adjustment
What We Don't Know
Well-characterized safety profile with FDA approval since 2005.
Published Research
31 studiesComparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis
Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials
Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes
Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy
Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes
A pilot trial of pramlintide home usage in adolescents with type 1 diabetes
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy
How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity
Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects
The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
Semaglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
StrongBeginnerA dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Liraglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
Quick Facts
- Class
- Amylin Analogue
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 31PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician